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OBJECTIVE— Risks of diabetes and cardiovascular disease are elevated worldwide in Indian
Asians. However, risks of other diabetes-related complications, i.e., foot ulceration and ampu-
tation, also with a vascular basis, are substantially lower in Asians than in white Europeans in the
U.K., possibly due to less neuropathy. We therefore compared signs, symptoms, and objective
quantitative measures of diabetic neuropathy and their risk factors in Indian Asians and
Europeans.
RESEARCH DESIGN ANDMETHODS— This was a cross-sectional study of a popu-
lation-based sample of age- and sex-matched adults with type 2 diabetes of European (95 male
and 85 female) and Asian (96 male and 84 female) descent in the U.K. Patients were assessed for
neuropathic symptoms, signs, nerve conduction, autonomic function, and quantitative sensory
testing. Peripheral vascular function and other potential risk factors for neuropathy were
measured.
RESULTS— Mean nerve conduction velocity Z scores were better in Asians (mean  SD
0.07  0.62) than in Europeans (0.11  0.60; P  0.007) and were explained by the
shorter height, fewer pack-years smoked, and higher transcutaneous oxygen levels (TCpO2)
in Indian Asians (P value for ethnic comparison attenuated to 0.2). Small fiber neuropathy
was less prevalent in Indian Asians compared with Europeans (odds ratio 0.58 [95% CI
0.37– 0.93]; P 0.02) and was primarily accounted for by better TCpO2 (0.70 [0.40 –1.21];
P  0.2).
CONCLUSIONS— Asians with diabetes have substantially less large and small fiber neu-
ropathy than Europeans, despite comparable traditional risk factors. Independent from smok-
ing, the lower risk of neuropathy in Asians is due to better skin microvascularization and may
help explain the substantially reduced Asian foot ulcer risk.
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P eople of Indian Asian descentworldwide have one of the highestrisks of type 2 diabetes; in the U.K.,
this is four times more prevalent than in
the general population (1). Most studies
indicate that risks of cardiovascular dis-
ease (CVD) in Indian Asians with diabetes
are greater than that in Europeans, reflect-
ing their overall greater predisposition to
CVD (2,3). Although many diabetes com-
plications have a vascular basis, we and
others have shown, paradoxically, that
risks of both foot ulceration and amputa-
tion are substantially lower (threefold and
fourfold, respectively) in Indian Asians
compared with Europeans (4,5) and that
lower rates of peripheral neuropathy in
Indian Asians may, to a large extent, ac-
count for this protection. To date, how-
ever, neuropathy assessments have been
crude, subjective, and not comprehen-
sive, and explanations for ethnic differ-
ences have not been sought.
This study was designed to compare
and account for differences in neuropathy
between Indian Asians and Europeans
with type 2 diabetes. We hypothesized
that Indian Asians would have preserved
large and small nerve function, using ob-
jective criteria, compared with Europe-
ans, and that this would only be partly
explained by differences in conventional
risk factors.
RESEARCH DESIGN AND
METHODS— This was a cross-
sectional study of a randomly selected
population-based sample of people with
type 2 diabetes of European and Indian
Asian descent drawn from primary care
registers in Manchester, U.K.
Type 2 diabetes was defined as a di-
agnosis made between age 30 and 39
years without insulin until at least 2 years
after diagnosis or a diagnosis at age 40
years and above regardless of initial treat-
ment. Because the mean age of diabetes
diagnosis is generally younger in Indian
Asians than in Europeans, broadening in-
clusion criteria for these individuals re-
duced the risk of a biased sample (5). A
5-year age stratum, ethnicity- and sex-
matched sample of Indian Asians and Eu-
ropeans with known type 2 diabetes was
drawn from eight primary care registers in
Central Manchester, all of which partici-
pate in ethnicity monitoring. Exclusion
criteria were lower limb amputation, psy-
chiatric disorder, known HIV positivity or
hepatitis carrier, terminal illness, or in-
ability to understand the study or provide
informed consent. We required 360 peo-
ple with diabetes (180 from each ethnic
group). To achieve this, a total sample of
682 eligible patients was selected for in-
vitation (52% Indian Asian and 51%
male; mean SD age 59 11 years). Of
this sample, 360 subjects (53% response
rate) gave written consent to participate
(50% Indian Asian and 47% male; age
58  10 years). Differences between re-
sponders and nonresponders for age, sex,
and ethnicity were not significant. This
study was approved by North Manchester
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Research Ethics Committee and by the
University of Manchester Committee on
the Ethics of Research on Human Beings.
Assessments
Consenting participants fasted at the
Manchester Royal Infirmary. A question-
naire was completed to obtain demo-
graphic data, medical history including
drugs, and lifestyle factors. Ethnicity was
checked, and country of birth was re-
corded (all Indian Asian participants were
first-generation migrants). Trained per-
sonnel performed all measurements with
standardized procedures and equipment
according to existing protocols. We mea-
sured height, weight, and waist and hip
circumference by a single measurement.
Fasting blood samples were taken
and sent to central laboratories for mea-
surement of A1C, fasting plasma glucose,
total cholesterol, HDL cholesterol, trig-
lycerides, and serum -glutamyltrans-
ferase (marker of alcohol consumption).
Fasting serum insulin was measured us-
ing a sensitive in-house radioimmunoas-
say as described previously (6).
Clinical complications of diabetes
Retinopathy and nephropathy were de-
fined as a history of physician-diagnosed
disease. Serum and early morning urinary
creatinine were measured on a Roche
MODULAR P Unit using the Jaffe method.
Urinary albumin was measured on a
Beckman Array analyzer using their
nephelometric assay. The urinary albu-
min-to-creatinine ratio was calculated.
CVD was defined as either a physi-
cian-diagnosed myocardial infarction, an-
gina, coronary artery bypass graft or
stroke, or a positive response to the Rose
Angina Questionnaire (7). Peripheral ar-
terial disease was defined as previous his-
tory of physician-diagnosed claudication
confirmed by lower limb arteriogram or a
positive response to the Edinburgh Clau-
dication Questionnaire (8).
Assessment and definition of
neuropathy
Clinical symptoms and signs of neu-
ropathy. Symptoms of muscle weakness,
sensation, and autonomic neuropathy
were determined from the Neuropathy
Symptoms and Change (NSC) validated
questionnaire (9). Signs were assessed us-
ing the modified Neuropathy Disability
Score (NDS), comprising pinprick, vibra-
tion, temperature sensation, and ankle re-
flexes. An NDS of 6 indicated clinical
neuropathy (10).
Large fiber neuropathy. Electrophysio-
logical assessments of peroneal, tibial,
and ulnar nerves (motor nerve conduc-
tion velocity [NCV] and maximum M-
wave amplitude) and sural and radial
nerves (NCV and amplitude) were per-
formed using a Dantec Counterpoint elec-
tromyograph system with surface
electrodes (skin temperature 32°C).
These assessments provide multiple, sim-
ilar, markers of peripheral nerve function;
therefore, we constructed Z scores. For
each individual, every NCV value was ex-
pressed as a Z score, i.e., (value in the
individual minus mean value in the over-
all study population) divided by the SD.
An average NCV Z score was calculated as
[(Z score sural NCV) (Z score peroneal
below fibular head NCV)  (Z score
peroneal knee NCV)  (Z score tibial
NCV) (Z score radial NCV) (Z score
ulnar NCV)]/6. Thus, the more positive
the result, the better the nerve function.
The response amplitude Z score was cal-
culated similarly.
Vibration perception threshold (VPT)
was assessed at the right and left great toes
in duplicate using a calibrated Neuroth-
esiometer (Horwell; Scientific Laboratory
Supplies, Nottingham, U.K.) (11). Read-
ings were averaged for analyses.
Small fiber neuropathy. Cooling detec-
tion thresholds (CDTs), heat pain mini-
mal threshold (HP-VAS0.5), and heat
pain intermediate threshold (HP-VAS5.0)
were evaluated on the dorsum of the left
foot using a CASE IV system (WR Medical
Electronics, Stillwater, MN) (12). For
thermal thresholds 95th percentile of
the CASE IV normality range was consid-
ered abnormal.
Autonomic function was assessed by
1) change in resting heart rate in response
to two separate cycles of deep breathing
(HRDB) using a CASE IV system (5th
percentile of the CASE IV normality range
was considered abnormal) (12) and 2)
change in systolic blood pressure from the
lying position to the standing position,
using a Critikon Dinamap 8100T plus
adult Dura-Cuf.
Algorithm for small fiber neuropathy
Small fiber neuropathy was classified us-
ing an algorithm incorporating the CASE
IV normality range for HRDB, CDT, HP-
VAS0.5, and HP-VAS5.0 (12). The sever-
ity of small fiber dysfunction was
stratified as normal (all tests normal),
mild (one abnormal test), moderate (two
abnormal tests), and severe (3 abnor-
mal tests). Small fiber neuropathy was de-
fined as the presence of mild, moderate,
or severe dysfunction.
Vascular function tests
The ankle-brachial pressure index (ABPI)
was determined using a Multi Dopplex II
ultrasound machine (Huntleigh Diagnos-
tics) and sphygmomanometer (Speidel &
Keller). Duplicate blood pressure read-
ings were averaged for each limb, and
ABPI was averaged for the right and left
sides combined. Abnormal ABPI was de-
fined as0.85 (13). Transcutaneous par-
tial pressure of oxygen (TCpO2) was
determined on the left foot dorsal surface
using a transcutaneous monitor and oxy-
gen sensor (Novametrix Medical Systems,
Wallingford, CT) (14). The patient was
semirecumbent, and foot skin tempera-
ture was maintained at 32°C. The cali-
brated TCpO2 sensor heated and
maintained skin temperature at 44°C.
This produced a local maximal vasodila-
tion to increase the permeability of the
skin to oxygen. Measurements were taken
after 20 min of stabilization.
Statistical analysis
NCV was selected as the primary outcome
of interest, as it is an early marker of dis-
ease and measured objectively. We esti-
mated that 360 patients (180 in each
ethnic group) would be sufficient, with
85% power to detect a difference in NCV
of at least one-third of a SD, at the 5%
significance level, making allowances for
missing data.
Measures of neuropathy were com-
pared between the ethnic groups as con-
tinuous variables, using simple means.
Normally distributed data were tested us-
ing a Student t test; non-normally distrib-
uted data were log transformed before
analysis or the Mann-Whitney test was
used. Multivariate linear regression mod-
els using ANOVA were constructed to ex-
plore the role of potential confounders
including glycemic control, height,
smoking, and hypertension and deter-
mine which factors could account for any
ethnic differences in measures of neurop-
athy. Categorical variables were com-
pared as simple proportions in the first
instance, using the 2 test for significance.
Logistic regression models were con-
structed to calculate odds ratios (ORs)
and adjust for important confounders. In-
teractions with ethnicity were also tested.
RESULTS— We studied 360 type 2
diabetic patients (Table 1). Indian Asians
(n  180) comprised 116 subjects origi-
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nating from Pakistan (64.4%), 26 subjects
from India (14.4%), 31 subjects from
Bangladesh (17.2%), and 7 subjects clas-
sified as Indian Asian–other (3.9%). The
white European group (n  180) com-
prised 157 subjects who were white Brit-
ish (87.2%) and 17 who were white Irish
(9.4%) with the remainder (n  6) being
white–other (3.3%).
Duration of diabetes was shorter in
Europeans than in Indian Asians (P 
0.01). Europeans were taller with a higher
BMI, greater smoking prevalence, and
higher alcohol intake (P 0.001). Signif-
icantly more Indian Asians were treated
with oral hypoglycemic agents, whereas
they were much less likely to be taking
lipid-lowering or antihypertensive thera-
pies (P  0.01).
Clinical signs and symptoms of
neuropathy
Neuropathy signs (NDS 6) were more
prevalent in Europeans (36 of 180, 20%)
than Indian Asians (27 of 178, 15%), al-
though this was not statistically signifi-
cant (P 0.2) (Fig. 1A). Overall symptom
reporting did not differ by ethnicity (total
mean NSC score for Europeans 2.2 2.2
and for Indian Asians 2.2 2.1, P 0.9);
however, Europeans reported greater loss
of peripheral sensation (0.29  0.77 vs.
0.13  0.45, P  0.018).
Large nerve fiber function
Indian Asians had higher mean values for
all motor and sensory NCVs and ampli-
tudes than Europeans (NCV and response
amplitude Z scores 0.07  0.62 and
0.08  0.69 [mean  SD] in Indian
Asians and 0.11  0.60 [P  0.007]
and 0.13  0.62 [P  0.003] in Euro-
peans (Fig. 1B). VPT did not differ by
ethnicity.
Small nerve fiber function
Cool detection threshold (Indian Asians
10.1  4.0 and Europeans 10.7  4.8;
P  0.2) or heat pain threshold (Indian
Asians 19.9 1.5 and Europeans 20.0
1.7, P  0.4) did not differ by ethnicity.
HRDB was greater in Indian Asians
(10.8  7.4 bpm) versus Europeans
(8.5  5.3 bpm; P  0.002) (Fig. 1C),
whereas the postural fall in systolic blood
pressure did not differ. The overall prev-
alence of small fiber neuropathy was
significantly lower in Indian Asians
(32%) than in Europeans (43%; P 
0.03) (Fig. 1A).
Ethnic differences in vascular
function
Peripheral vascular function was more fa-
vorable in Indian Asians than Europeans,
i.e., Indian Asians were less likely to re-
port claudication or have an abnormal
ABPI, and had higher TCpO2 levels (Ta-
ble 1). Adjustment for ethnic differences
in smoking status, height, lipid levels,
A1C, or ABPI had no impact on the ethnic
difference in TCpO2 levels (data not
shown).
Table 1—Demographic and clinical characteristics of ethnic groups
Indian Asians White Europeans P value*
n 180 180
Sex (male/female) 95/85 96/84 0.9
Age (years) 57.4  9.9 59.1  9.7 0.09
Duration diabetes (years) 9.4  7.5 7.0  5.7 0.001
Height (m) 1.61  9.3 1.65  9.8 0.0001
Weight (kg) 77.2  14.8 93.3  19.3 0.0001
BMI (kg/m2) 29.7  5.5 34.1  6.5 0.0001
Waist (cm)
Men 96.7  13.1 106.6  12.7 0.0001
Women 97.1  12.8 102.7  15.1 0.01
Hips (cm)
Men 99.6  8.1 105.4  8.7 0.0001
Women 103.1  11.3 111.0  15.6 0.0001
Waist-to-hip ratio
Men 0.97  0.09 1.01  0.07 0.0001
Women 0.94  0.08 0.92  0.08 0.2
Fasting plasma glucose (mmol/l) 7.7  2.2 8.0  2.3 0.2
A1C (%) 8.1  1.6 7.9  1.7 0.3
Total cholesterol (mmol/l) 4.3  1.0 4.7  1.1 0.004
HDL cholesterol (mmol/l) 1.3  0.3 1.3  0.4 0.7
Fasting triglycerides (mmol/l) 1.4 (1.1, 1.9) 1.7 (1.2, 2.4) 0.005
Insulin (mU/l) 17.1 (9.6, 27.0.1) 18.2 (11.5, 28.6) 0.44
-Glutamyltransferase (U/l) 35.7  34.4 58.7  56.0 0.0001
Creatinine (mol/l) 87.2  31.2 85.9  27.0 0.7
Urinary albumin-to-creatinine ratio 1.5 (0.7, 2.5) 1.4 (0.6, 3.0) 0.6
Retinopathy (%) 14 12 0.6
Nephropathy (%) 6 4 0.3
Hypertension (%) 54 74 0.0002
Myocardial infarction (%) 17 13 0.3
Angina (%) 23 17 0.2
Coronary artery bypass graft (%) 14 9 0.1
Resting heart rate (bpm) 76  14 75  13 0.8
Ankle systolic blood pressure (mmHg) 136  22 142  31 0.06
Brachial systolic blood pressure (mmHg) 123  17 127  17 0.02
ABPI 0.85 (%) 4.0 9.1 0.05
Lower limb vascular intervention (%) 3 9 0.03
Claudication (%) 7 15 0.01
TCpO2 (mmHg) 61  12 56  13 0.0001
Pack-years smoked (%) 0.0001
None 74 36
20 14 22
	20 11 42
Drink alcohol  once a week (%) 5 42 0.0001
Insulin (%) 19 23 0.4
Oral antidiabetic drugs (%) 87 76 0.007
Antihypertensive drugs (%) 61 77 0.001
Lipid-lowering drugs (%) 57 71 0.006
Other coronary heart disease drugs (%) 15 18 0.4
Data are % prevalence, means  SD, or geometric means (25th, 75th percentiles). *P value for ethnic
difference.
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Explanations for ethnic differences
in large nerve fiber function
Smoking had little impact in accounting
for the ethnic difference in peripheral
nerve large fiber function (NCV Z scores)
(Table 2). Height appeared to have the
greatest single impact, with a multivar-
iate model, including height, pack-
years smoked, and TCpO2 substantially
attenuating the ethnic difference in
nerve function, losing statistical signifi-
cance (P  0.2). An analysis restricted
to never smokers showed that Indian
Asians maintained greater NCV Z scores
than their European counterparts (0.13
[95% CI 0.025– 0.24] versus 0.06
[0.23 to 0.10], P  0.05).
Explanations for ethnic differences
in small fiber neuropathy
The risk (OR) of small fiber neuropathy
was 0.61 (P 0.03) in Indian Asians ver-
sus Europeans (Table 3). Adjustment for
the lower smoking rates and shorter
height in Indian Asians did not apprecia-
bly alter this ethnic difference in risk, but
some attenuation was observed with ad-
justment for ABPI and for TCpO2. A mul-
tivariate model with all of these factors
attenuated the OR to 0.70 (P 0.2). The
impacts of ABPI (P  0.02) and TCpO2
(P  0.02) in this multivariate model
were statistically significant and indepen-
dent of each other. As a sensitivity analy-
sis, we also compared small fiber
neuropathy in never smokers, and the
ethnic difference persisted (n  178):
31% in Indian Asians and 52% in Euro-
peans (P 0.009). Only BMI appreciably
accounted for the ethnic difference in au-
tonomic small fiber function, i.e., HRDB
(10.4 vs. 9.1 bpm, P  0.08, in Indian
Asians vs. Europeans) (Table 3); height
alone had negligible impact.
CONCLUSIONS— We show, using
objective measurements, that both so-
matic and autonomic nerve function is
better preserved in Indian Asians than in
Europeans with diabetes. Healthier pe-
ripheral vascular function was the key
modifiable determinant of this protection
from neuropathy in Indian Asians with
independent contributions from low
smoking rates and shorter height.
Although others have reported favor-
able levels of neuropathy in Indian
Asians, these reports relied largely on sub-
jective, crude measures of advanced neu-
ropathy, and explanations for ethnic
differences were not explored (4,5,15).
Indian Asians with newly diagnosed dia-
betes in the UK Prospective Diabetes
Study had lower rates of neuropathy than
Europeans (4 compared with 13%) diag-
nosed using the vibration sensation
threshold (15). However, individuals
with preexisting CVD were excluded,
and, as this is more common in Indian
Asians, may have biased the comparison.
In our previous large, population-based
studies, we also showed that the preva-
lence of neuropathy was significantly
lower in Indian Asians than in Europeans
with diabetes (4,5), but again objective
measures were not used. Varying rates of
peripheral neuropathy from the Indian
subcontinent have been reported (3–
25%) (16,17), but because assessment
methods vary, it is difficult to compare these
rates directly with European samples.
Height is often cited as a key risk fac-
tor for neuropathy; it is therefore not sur-
prising that the shorter height of Indian
Asians contributes to their lower risk
(18). The additional significant contribu-
tions from lower smoking rates plus fa-
vorable peripheral blood flow indicators
(TCpO2 and ABPI) support the vascular
theory for neuropathy etiology (19). Oth-
ers report that both macrovascular (sys-
tolic blood pressure, conduit arterial
stiffening, and thickness) (20) and micro-
vascular (reduced capillary blood flow
due to endothelium-dependent and inde-
pendent mechanisms) (21) abnormalities
are key determinants of nerve fiber func-
Figure 1—Indexes of neuropathy by ethnicity: Indian Asians and Europeans. A: Neuropathy
prevalence (percent). B: Nerve conduction studies (Z scores) (mean  SE). C: Autonomic nerve
function (mean SD). *Significantly different between the two groups, P 0.05. **Significantly
different between the two groups, P  0.01. SBP, systolic blood pressure.
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tion in type 2 diabetes. These abnormali-
ties are strongly correlated in individuals
and populations. However, we show that
despite the anticipated greater macrovas-
cular burden, Indian Asians have sub-
stantially better TCpO2 (not wholly
explained by lower smoking rates), and
that this contributes to the favorable neu-
ropathy status. TCpO2, or tissue oxygen-
ation, in the lower limb is an indicator of
“upstream blood flow” and can be af-
fected by large vessel occlusion and arte-
riole and/or capillary function (22). In
addition, we show that peripheral arterial
disease, as measured by ABPI, is lower in
Indian Asians and makes a significant and
independent contribution to account for
ethnic differences in peripheral neuropa-
thy, comparable to TCpO2. Our TCpO2
data, therefore, more likely reflect mi-
crovessel (capillary and arteriole) func-
tion rather than large vessel flow. These
findings suggest that microvascular flow
may explain ethnic differences in the eti-
ology of neuropathy. The reason that
Asians have better microvascular func-
tion, despite poorer macrovascular func-
tion is, as yet, unclear.
Elsewhere, glycemia, triglycerides,
and insulin resistance have been linked
with clinical polyneuropathy in type 2
diabetes (23,24). However, we found that
these factors had little effect on account-
ing for ethnic differences and were over-
whelmed by the impact of tissue
oxygenation, probably indicating that this
is a better downstream measure of the
composite of vascular insults.
The marked ethnic differences in ob-
jective nerve electrophysiological mea-
sures were largely not reflected in
reported neuropathic symptoms or elic-
ited signs. This may reflect the greater
sensitivity of electrophysiology, detecting
very early signs of disease, and the subjec-
tivity of signs and symptoms. The latter
is particularly important in ethnic com-
parison studies, in which interpretation
and reporting may differ. Our findings
underline the importance of objective as-
sessments. Our study is large and repre-
sentative of the general population with
diabetes, as sampling was from primary
rather than hospital care, the former hav-
ing universal coverage. In addition, be-
cause health care is free at the point of
delivery, differences in access to health
care should not have influenced our find-
ings. One limitation of this study is that it
is cross-sectional, whereas a longitudinal
assessment of neuropathy development
would substantiate our findings. A possi-
ble explanation for the lower prevalence
of neuropathy observed in Indian Asians
is that the elevated risk of premature car-
diovascular death had selected out Indian
Asians with current or high risk of subse-
quent neuropathy. However, selective
mortality cannot be the full explanation
because we estimate that premature CVD
mortality would have to be 3- to 4-fold
greater, rather than the observed 1.5- to
2-fold increase in younger Indian Asians
than Europeans, to account for the lower
neuropathy prevalence detected in our
study.
We therefore conclude that both pe-
ripheral and autonomic neuropathy are
less prevalent in Indian Asians than in Eu-
ropeans with type 2 diabetes. Further-
more, lower height, less smoking, and a
more favorable microcirculation, rather
than conventional risk factors such as gly-
cemic control and hyperlipidemia, seem
to account independently for the Indian
Asian preservation of peripheral nerve
function. These data may explain why In-
dian Asians are protected against diabetic
foot ulceration, as sensitivity to trauma via
peripheral large fiber function and auto-
nomic neurogenic control of cutaneous
blood flow are primary factors in the risk
of plantar tissue breakdown and delayed
wound healing (4,25).
Acknowledgments— This study was sup-
ported by Diabetes U.K.
Table 2—Large nerve fiber function (mean NCV Z score for sural, peroneal, tibial, radial, and
ulnar nerves combined) with 95% CIs, by ethnicity
Adjustment factors Indian Asian European P value*
Unadjusted 0.07 (0.02 to 0.16) 0.11 (0.20 to 0.02) 0.007
Age  diabetes duration 0.09 (0.002 to 0.18) 0.13 (0.22 to 0.04) 0.001
Age  duration  height 0.04 (0.04 to 0.12) 0.08 (0.16 to 0.01) 0.06
Age  duration  pack-years
smoked 0.07 (0.03 to 0.16) 0.11 (0.20 to 0.01) 0.01
Age  duration  TCpO2 0.11 (0.02 to 0.20) 0.09 (0.18 to 0.001) 0.003
Age  duration  height 
pack-years smoked 
TCpO2 0.05 (0.04 to 0.14) 0.03 (0.12 to 0.06) 0.2
*P value for ethnic difference.
Table 3—Regression modeling: small fiber neuropathy by ethnicity
Risk of small fiber neuropathy in Indian Asians vs. Europeans with adjustment for covariates
Adjustment factors Odds ratio (95% CI) P value*
Unadjusted 0.61 (0.39–0.95) 0.03
Age  diabetes duration 0.58 (0.37–0.93) 0.02
Age  duration  pack-years smoked 0.58 (0.35–1.00) 0.04
Age  duration  pack-years smoked  height 0.61 (0.36–1.02) 0.06
Age  duration  pack-years smoked  ABPI 0.85 0.64 (0.38–1.08) 0.09
Age  duration  pack-years smoked  TCpO2 0.63 (0.37–1.08) 0.09
Multivariate model: age  duration  pack-years
smoked  height  ABPI 0.85  TCpO2 0.70 (0.40–1.21) 0.2
Autonomic nerve function (heart rate decline in response to deep breathing, bpm) by
ethnicity
Adjustment factors
Odds ratio (95% CI)
P value*Indian Asian European
Unadjusted 10.8 (9.8–11.8) 8.5 (7.5–9.5) 0.002
Age  diabetes duration 10.8 (9.8–11.7) 8.7 (7.8–9.6) 0.003
Age  duration  height 10.9 (9.9–11.8) 8.6 (7.7–9.6) 0.002
Age  duration  weight 10.4 (9.4,11.4) 9.0 (8.0–10.0) 0.07
Age  duration  BMI 10.4 (9.4–11.3) 9.1 (8.1–10.0) 0.08
*P value for ethnic difference.
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